Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012 : Market Research Report

Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012

Published: Nov. 1, 2005 - 91 Pages

List of Tables
List of Figures
Executive Summary: Objectives of the Report; Research Methodology
Chapter 1 Introduction to Mood Disorders and Cognitive Impairment: Depression; Prevalence; Aetiology of Depression; Types of Depression; Major depression; Dysthymia; Bipolar Disorder; Symptoms of Depression; Anxiety Disorders; Prevalence; Cognitive Impairments and Memory Deficits; Prevalence; Pharmacotherapy for Cognitive Impairment
Chapter 2 The Global Market for Mood Disorders: Depression and Anxiety: Mood Disorders: Depression and Anxiety; Market Overview of Drugs to Treat Depression and Anxiety Disorders; Market Analysis and Insights for Drugs to Treat Depressive Illnesses; Market Analysis: Antidepressant Therapy Area; Prozac (Fluoxetine) - Eli Lilly; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Cymbalta (Duloxetine) - Eli Lilly/Boehringer Ingelheim; Product Overview; Indications and Supplementary Labelling; Sales Prospects; Commercial Outlook; Zoloft/Lustral (Sertraline) - Pfizer; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Seroxat/Paxil/Deroxat (Paroxetine) - GlaxoSmithKline; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Wellbutrin (Bupropion) - GlaxoSmithKline; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Effexor (Venlafaxine) - Wyeth; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Remeron/Zispin (Mirtazapine) - Organon/Akzo Nobel; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Cipramil/Celexa (Citalopram) - Lundbeck/Forest Laboratories; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Cipralex/Lexapro (Escitalopram) - Lundbeck/Forest; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Future Considerations and Market Insights for the Antidepressant Market; Pipeline Antidepressants; Pipeline Focus; Valdoxan (Agomelatine) - Servier; Pharmacotherapeutics for Cognitive Impairment and /Memory Deficits; Future Market Focus - Age-Related Cognitive Decline; Nootropil (Piracetam) - UCB Pharma; Companies Developing Drugs for Cognitive and Memory Impairment; EGb 761/Tanakan - Ipsen
Chapter 3 Drugs in Research and Development: Pipeline Mood Stabilizers and Drugs for Cognitive Impairment; Drugs in Development for Mood Disorders: Antidepressants and Anxiolytics; Depression and Anxiety: Research and Development Overview; Drugs in Development for Cognitive and Memory Impairment; Cognitive/Memory Impairment - Research and Development Overview
Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining: Data Analysis, Therapy Forecasting, and Prospect Mining; Market Analysis and Therapy Forecasting; Antidepressants and Anxiolytics; Therapy Area Forecasts; Comparative Analysis: Antidepressant/Anxiolytic Product Sales; Prospect Mining; Mood Disorders: Depression and Anxiety; Cognitive and Memory Impairment; Therapy Area Forecasts, 2012 and 2020
Chapter 5 Report Synopsis: Depressive/Anxiety and Cognitive/Memory Impairment - Key Data Points; Bibliography and Reference Sources
List of Tables: Table 1.1 Role of Neurotransmitters in Depression; Table 1.2 Symptoms of Depression and Bipolar Disorder/Mania; Table 1.3 Major Anxiety Disorders; Table 1.4 Causes of Dementia; Table 2.1 Estimated Global Sales & Forecasts of Leading Antidepressants, 2004-2012 (US$m); Table 2.2 Estimated Annual Growth Rates of Leading Antidepressants (%), 2004-2012; Table 2.3 Leading Antidepressants Ranked by Sales, 2005 & 2012; Table 2.4 Primary and Secondary Indications for Antidepressants; Table 2.5 Estimated Sales (US$) and Annual Growth (%) of Prozac, 2005-2012; Table 2.6 Estimated Sales (US$) and Annual Growth (%) of Cymbalta, 2005-2012; Table 2.7 Estimated Sales (US$) and Annual Growth (%) of Zoloft, 2005-2012; Table 2.8 Estimated Sales (US$) and Annual Growth (%) of Seroxat/Paxil, 2005-2012; Table 2.9 Estimated Sales (US$) and Annual Growth (%) of Wellbutrin, 2005-2012; Table 2.10 Estimated Sales (US$) and Annual Growth (%) of Effexor, 2005-2012; Table 2.11 Estimated Sales (US$) and Annual Growth (%) of Remeron, 2005-2012; Table 2.12 Estimated Sales (US$) and Annual Growth (%) of Cipramil/Celexa, 2005-12; Table 2.13 Estimated Sales (US$) and Annual Growth (%) of Cipralex/Lexapro, 2005-12; Table 2.14 Drugs in Development for Cognitive and Memory Impairment, 2005 (partial); Table 3.1 Drugs in Development for Depression and Anxiety, 2005; Table 3.2 Drugs in Development for Cognitive and Memory Impairment, 2005; Table 4.1 Global Drug Market for Antidepressants and Anxiolytics (US$m) 2004-2012; Table 4.2 Therapy Area Forecasts for the Global Mood Disorders and Cognitive Impairment Market Sectors, 2012 and 2020
List of Figures: Figure 2.1 Estimated Global Sales of Leading Antidepressants, 2005 & 2012; Figure 2.2 Estimated Market Share of Leading Antidepressants, 2005 & 2012; Figure 4.1 Therapy Area Forecasts for Antidepressants and Anxiolytics, 2005 & 2012 (US$m); Figure 4.2 Comparative Analysis of Leading Antidepressants and Anxiolytics 2004-2012; Figure 4.3 Key Antidepressant/Anxiolytic Prospects in the CNS Development Pipeline, 2005; Figure 4.4 Key Cognitive and Memory Impairment Prospects in the CNS Development Pipeline, 2005

Abstract

This report examines the global mood disorder sector and highlights the converging market stimulators and inhibitors that may lead to a market decline from an estimated US$17.4 billion in 2005 to US$15 billion in 2012. Key factors discussed include patent expirations of leading antidepressants over the next 7 years, increased generic substitution trends, safety concerns over SSRIs; cost-containment in prescribing; and litigation activities between research-based and generic companies. Key market stimulators identified to buffer the decline include the introduction of new drug classes, new formulations, line extensions, increased patient populations, and treatment resistance. The report also evaluates the emerging market sector of cognitive and memory impairment and shows the extent of R&D activities within the field. Analysis of both sectors reveals candidates that have top-line earning prospects and also provides an insight into potential licensing or acquisition opportunities in promising psychopharmacotherapy market subsectors.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

advertise with us

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012

Table of Contents

Abstract